Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 151 No. 2728 (2021)

The burden of systemic sclerosis in Switzerland – the Swiss systemic sclerosis EUSTAR cohort

DOI
https://doi.org/10.4414/smw.2021.20528
Cite this as:
Swiss Med Wkly. 2021;151:w20528
Published
14.07.2021

Summary

OBJECTIVES

Characteristics of Swiss patients with systemic sclerosis have not been described so far. The aim of the current study was to identify unmet needs in comparison with other European countries that could inform specific interventions to improve the care of systemic sclerosis patients.

METHODS

We analysed Swiss and other European systemic sclerosis patients registered in European Scleroderma Trials And Research (EUSTAR) and the Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) cohort. Demographics, clinical profiles, organ involvement and survival of established, early/mild and very early / very mild systemic sclerosis patients were described and compared between the cohorts.

RESULTS

We included 679 Swiss and 8793 European systemic sclerosis patients in the analysis. Over 95% of patients in both cohorts were Caucasian, disease subsets were similar, and no age difference was found. The Swiss cohort had more male patients (25% vs 16% European, p = 0.005) and higher prevalence of early/mild and very early / very mild patients (26.1 vs 8.5% European and 14.9% vs 6.7% European, respectively, both p <0.0001). Disease duration in established systemic sclerosis patients at first presentation was numerically shorter but not significant in the Swiss cohort: 5.0 years (1–12) Swiss vs 6.0 years (2–12) years European, p = 0.055). Despite the earlier referral of Swiss patients to systemic sclerosis expert centres, they showed evidence of more severe disease, particularly in the limited cutaneous systemic sclerosis subset, but no differences in overall survival on longitudinal follow-up were observed.

CONCLUSION

This is the first report of the national Swiss EUSTAR cohort. It identifies earlier referral to systemic sclerosis expert centres, before major organ damage occurs, and when outcome can still be modified, as a priority to improve care of patients with systemic sclerosis.

References

  1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989–2003. doi:.https://doi.org/10.1056/NEJMra0806188
  2. Wirz EG, Jaeger VK, Allanore Y, Riemekasten G, Hachulla E, Distler O, et al.; EUSTAR coauthors. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis. 2016;75(7):1285–92. doi:.https://doi.org/10.1136/annrheumdis-2015-207271
  3. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008;37(4):223–35. doi:.https://doi.org/10.1016/j.semarthrit.2007.05.003
  4. Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–15. doi:.https://doi.org/10.1136/ard.2009.114264
  5. Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017;76(7):1207–18. doi:.https://doi.org/10.1136/annrheumdis-2016-210503
  6. Walker UA, Tyndall A, Czirják L, Denton CP, Farge-Bancel D, Kowal-Bielecka O, et al.; EUSTAR co-authors. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis. 2009;68(6):856–62. doi:.https://doi.org/10.1136/ard.2008.091348
  7. Walker UATA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66(6):754–63. doi:.https://doi.org/10.1136/ard.2006.062901
  8. Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev. 2010;9(5):A311–8. doi:.https://doi.org/10.1016/j.autrev.2009.11.003
  9. Masi AT. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23(5):581–90. doi:.https://doi.org/10.1002/art.1780230510
  10. LeRoy EC, Medsger TA, Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28(7):1573–6.
  11. Scussel Lonzetti L, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: Addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. 2001;??:735–6.
  12. Wollheim FA. Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford). 2005;44(10):1212–6. doi:.https://doi.org/10.1093/rheumatology/keh671
  13. Matucci-Cerinic M, Allanore Y, Czirják L, Tyndall A, Müller-Ladner U, Denton C, et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis. 2009;68(9):1377–80. doi:.https://doi.org/10.1136/ard.2008.106302
  14. Matucci-Cerinic M, Bellando-Randone S, Lepri G, Bruni C, Guiducci S. Very early versus early disease: the evolving definition of the ‘many faces’ of systemic sclerosis. Ann Rheum Dis. 2013;72(3):319–21. doi:.https://doi.org/10.1136/annrheumdis-2012-202295
  15. Valentini G, Cuomo G, Abignano G, Petrillo A, Vettori S, Capasso A, et al. Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford). 2011;50(2):317–23. doi:.https://doi.org/10.1093/rheumatology/keq176
  16. Bellando-Randone S, Matucci-Cerinic M. From Raynaud’s Phenomenon to Very Early Diagnosis of Systemic Sclerosis- The VEDOSS approach. Curr Rheumatol Rev. 2013;9(4):245–8. doi:.https://doi.org/10.2174/157339710904140417124819
  17. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–55. doi:.https://doi.org/10.1136/annrheumdis-2013-204424
  18. Andréasson K, Saxne T, Bergknut C, Hesselstrand R, Englund M. Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria. Ann Rheum Dis. 2014;73(10):1788–92. doi:.https://doi.org/10.1136/annrheumdis-2013-203618
  19. Jordan S, Maurer B, Toniolo M, Michel B, Distler O. Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice. Rheumatology (Oxford). 2015;54(8):1454–8. doi:.https://doi.org/10.1093/rheumatology/keu530
  20. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al.; EUSTAR Group. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70(3):476–81. doi:.https://doi.org/10.1136/ard.2010.136929
  21. Minier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Czirják L, et al.; EUSTAR co-workers; EUSTAR co-workers. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis. 2014;73(12):2087–93. doi:.https://doi.org/10.1136/annrheumdis-2013-203716
  22. Blaja E, Jordan S, Mihai CM, Dobrota R, Becker MO, Maurer B, et al. The Challenge of Very Early Systemic Sclerosis: A Combination of Mild and Early Disease? J Rheumatol. 2021;48(1):82–6. doi:.https://doi.org/10.3899/jrheum.190976
  23. Federal Office of Public Health HaAID. Nationales Konzept Seltene Krankheiten 3003 Bern: Federal Office of Public Health; 2014 [updated 15 October 2015. Available from: https://www.bag.admin.ch/bag/de/home/themen/mensch-gesundheit/seltene-krankheiten/nationales-konzept-seltene-krankheiten.html.
  24. Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, et al.; EUSTAR Co-authors. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2012;71(8):1355–60. doi:.https://doi.org/10.1136/annrheumdis-2011-200742
  25. Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017;2(1):11–8. doi:.https://doi.org/10.5301/jsrd.5000231
  26. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66(6):754–63. doi:.https://doi.org/10.1136/ard.2006.062901
  27. Valentini G, Bencivelli W, Bombardieri S, D’Angelo S, Della Rossa A, Silman AJ, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis. 2003;62(9):901–3. doi:.https://doi.org/10.1136/ard.62.9.901
  28. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202–5.
  29. Cutolo M, Pizzorni C, Sulli A. Die Video-Kapillarmikroskopie der Nagelfalz bei systemischer Sklerose [Nailfold video-capillaroscopy in systemic sclerosis]. Z Rheumatol. 2004;63(6):457–62. doi:.https://doi.org/10.1007/s00393-004-0673-5
  30. Mayes MD, Lacey JV, Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48(8):2246–55. doi:.https://doi.org/10.1002/art.11073
  31. Arias-Nuñez MC, Llorca J, Vazquez-Rodriguez TR, Gomez-Acebo I, Miranda-Filloy JA, Martin J, et al. Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Medicine (Baltimore). 2008;87(5):272–80. doi:.https://doi.org/10.1097/MD.0b013e318189372f
  32. Simeón CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford). 2003;42(1):71–5. doi:.https://doi.org/10.1093/rheumatology/keg033
  33. Joven BE, Almodovar R, Carmona L, Carreira PE. Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum. 2010;39(4):285–93. doi:.https://doi.org/10.1016/j.semarthrit.2009.06.002
  34. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis. 1998;57(11):682–6. doi:.https://doi.org/10.1136/ard.57.11.682
  35. Hoffmann-Vold AM, Molberg Ø, Midtvedt Ø, Garen T, Gran JT. Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis. J Rheumatol. 2013;40(7):1127–33. doi:.https://doi.org/10.3899/jrheum.121390
  36. Czirják L, Kumánovics G, Varjú C, Nagy Z, Pákozdi A, Szekanecz Z, et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis. 2008;67(1):59–63. doi:.https://doi.org/10.1136/ard.2006.066340
  37. Federal Office of Public Health FOPH. Switzerland’s population 2016 Neuchatel, Switzerland 2016 [updated 2016] Available from: https://www.bfs.admin.ch/bfs/de/home/statistiken/bevoelkerung.html.
  38. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial. Ann Intern Med. 1996;124(8):699–707. doi:.https://doi.org/10.7326/0003-4819-124-8-199604150-00001
  39. Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al.; EUSTAR group. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11):1897–905. doi:.https://doi.org/10.1136/annrheumdis-2017-211448
  40. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al.; SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019;380(26):2518–28. doi:.https://doi.org/10.1056/NEJMoa1903076
  41. Hoffmann-Vold A-M, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsotti S, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. The Lancet Rheumatology. 2020;2(2):e71–83. doi:.https://doi.org/10.1016/S2665-9913(19)30144-4
  42. Kuwana M, Distler O. Recent progress and missing gaps to achieve goal in the care of systemic sclerosis–associated interstitial lung disease. J Scleroderma Relat Disord. 2020;5(2_suppl):3–5. doi:.https://doi.org/10.1177/2397198320902551
  43. Volkmann ER, Fischer A. Update on Morbidity and Mortality in Systemic Sclerosis-Related Interstitial Lung Disease. J Scleroderma Relat Disord. 2021;6(1):11–20. doi:.https://doi.org/10.1177/2397198320915042
  44. Volkmann ER. Natural History of Systemic Sclerosis-Related Interstitial Lung Disease: How to Identify a Progressive Fibrosing Phenotype. J Scleroderma Relat Disord. 2020;5(2_suppl):31–40. doi:.https://doi.org/10.1177/2397198319889549
  45. Roofeh D, Distler O, Allanore Y, Denton C, Khanna D. Treatment of systemic sclerosis–associated interstitial lung disease: Lessons from clinical trials. J Scleroderma Relat Disord. 2020;5(2_suppl):61–71. doi:.https://doi.org/10.1177/2397198320903208
  46. Walker UA, Saketkoo LA, Distler O. Haematopoietic stem cell transplantation in systemic sclerosis. RMD Open. 2018;4(1):e000533. doi:.https://doi.org/10.1136/rmdopen-2017-000533
  47. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al.; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–39. doi:.https://doi.org/10.1136/annrheumdis-2016-209909
  48. Jaeger VK, Wirz EG, Allanore Y, Rossbach P, Riemekasten G, Hachulla E, et al.; EUSTAR co-authors. Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS One. 2016;11(10):e0163894. doi:.https://doi.org/10.1371/journal.pone.0163894
  49. Hoffmann-Vold AM, Fretheim H, Halse AK, Seip M, Bitter H, Wallenius M, et al. Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. Am J Respir Crit Care Med. 2019;200(10):1258–66. doi:.https://doi.org/10.1164/rccm.201903-0486OC

Most read articles by the same author(s)

1 2 > >>